Now that it's teamed up with Novartis' consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's OTC business is bigger than ever. But its payroll is about to get smaller, with 350 layoffs hitting the operation.
Zimmer will close its Carlsbad, CA, dental headquarters following its looming $13 billion merger with Biomet, resulting in an unspecified number of layoffs. The plant closure will occur in 12 months, say internal company emails sent to both companies' employees that were obtained by FierceMedicalDevices.
The big asset swap between GlaxoSmithKline and Novartis may have given each just what it wanted, but the deal continues to play out poorly for workers, with GSK planning to close its Pittsburgh office where it has about 275 employees working for its consumer health unit.
Japan's Eisai has decided to follow the cost-cutting trend of many of its multinational counterparts and lay off a quarter of its U.S. commercial and regional corporate services units, which currently employ about 850 people. The unit said the 200-plus staff reductions would not affect manufacturing or R&D units.
Japan's Eisai is taking out the budget ax and chopping more than 200 jobs out of its U.S. operations. A spokesperson for the company tells FierceBiotech tonight that the cuts will center on Eisai's commercial and regional corporate services units, which employ about 850 people. She adds: "The restructuring will not affect our manufacturing or R&D units."
Just a couple of weeks after fellow Japanese drugmaker Daiichi Sankyo announced a layoffs drive as part of a U.S. revamp, Eisai is doing the same. Two of its units in the country are headed for a 25% shrinkage, the company said Thursday.
The layoff roller-coaster ride has lots of ups and downs. And so while the top 10 announced layoffs in 2011-2013 averaged nearly 30,000 a year, there were far fewer in 2014. In fact, so few that this year we tallied only 10,691 among 7 companies.
After closing its deal for Salix Pharmaceuticals, Valeant wasted no time getting down to business with the cost-cutting it's known for. And now, North Carolina's Triangle area has another 250-plus pharma layoffs to add to a growing list.
Ophthalmic and surgical sutures for holding tissue together after medical procedures will no longer be made in Exeter Township, PA, thanks to the upcoming closure of the Surgical Specialties' manufacturing plant in the Philadelphia suburb. It will come at a cost of 254 jobs.
Last year, GlaxoSmithKline announced plans to slim down its Research Triangle Park, NC-based operations, chopping 900 jobs. Now, it's telling state officials that almost 200 workers are heading for the door.